CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF IND APPLICATION FOR ICF001 BY THE NMPA

This announcement is made by CF PharmTech, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the latest research and development of the Group.

INTRODUCTION

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the investigational new drug ("**IND**") application (the "**Application**") for ICF001 (the "**Product**"), the Company's independently developed inhalation powder candidate, has been accepted by the National Medical Products Administration of the People's Republic of China (the "**NMPA**"). The relevant information is hereby announced as follows:

Product name	:	ICF001 (inhalation powder)
Application type	:	IND application
Registration category	:	Class 2.1 chemical drug
Acceptance number	:	CXHL2600306/CXHL2600307/ CXHL2600308/CXHL2600309/ CXHL2600310/CXHL2600311
Applicant	:	CF PHARMTECH GUANGZHOU LIMITED (a subsidiary of the Company), the Company

ICF001 is an innovative long-acting inhalation powder candidate independently developed based on a prodrug technology platform, designed specifically for the treatment of pulmonary hypertension and related severe pulmonary diseases. In terms of molecular design and mechanism of action, the Product transforms the active molecule into a prodrug through specific chemical modifications. Upon inhalation and deposition in the lungs, it relies on the slow cleavage by endogenous enzymes in the lung tissue to continuously release the active ingredient. Based on preclinical studies, this design is expected to deliver the drug to the deep lung tissue while blunting the peak blood concentration (C_{max}) at the initial stage of administration and prolonging local drug exposure, thereby exploring the potential to optimize the pharmacokinetic (PK) profile of the drug.

STRATEGIC SIGNIFICANCE

The initial indications for ICF001 are pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). PAH is a fatal rare disease, whereas PH-ILD represents an area with a larger patient base and relatively limited existing therapies. In recent years, cutting-edge scientific research and clinical explorations of international projects of the same class further suggest that the specific pathway targeted by ICF001 has dual potential in anti-pulmonary hypertension and anti-fibrosis. Therefore, based on this unique mechanism, ICF001 possesses broad potential to expand into larger patient populations, such as those with pulmonary fibrosis associated with interstitial lung disease, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), in the future.

The acceptance of the Application marks an important milestone for the Group in entering clinical development for its high-barrier respiratory pipeline. The Company believes that the research and development of ICF001 is strategically focused on exploring its potential improvements in tolerability and titration efficiency, specifically focusing on the following directions: First, through the synergistic optimization of molecular structure and formulation process, it strives to improve drug payload efficiency, reduce the administration burden, and enhance airway tolerability; second, it aims to optimize the in vivo exposure profile, improving the overall exposure performance while controlling the peak blood concentration, to support a more controllable dosing strategy. If the relevant mechanisms and clinical benefits are further verified in subsequent studies, it is expected to support a more operable and controllable inhalation administration strategy, enhance long-term medication adherence, optimize efficacy potential, and broaden the clinical accessibility of the drug.

The Group will maintain active communication with the NMPA and advance subsequent clinical activities in accordance with regulatory requirements.

RISK WARNING

The acceptance of the Application represents an administrative step in the review process and does not constitute marketing approval. The Product is subject to further review and assessment by the NMPA, and there is no assurance that the Application will be approved. Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Given such risks and uncertainties, **shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities — from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms — the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening international presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, March 13, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.